Pluri Inc. (PLUR)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Pluri Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | 1.30 | 1.31 | 1.18 | 1.27 | 49,404 |
| Nov 2, 2026 | 1.28 | 1.30 | 1.20 | 1.20 | 98,937 |
| Oct 30, 2026 | 1.30 | 1.30 | 1.20 | 1.24 | 29,336 |
| Oct 29, 2026 | 1.25 | 1.34 | 1.18 | 1.20 | 38,526 |
| Oct 28, 2026 | 1.20 | 1.43 | 1.19 | 1.23 | 227,584 |
| Oct 27, 2026 | 1.21 | 1.30 | 1.15 | 1.19 | 132,783 |
| Oct 26, 2026 | 1.18 | 1.36 | 0.9600 | 1.12 | 490,458 |
| Oct 23, 2026 | 1.06 | 1.24 | 0.9650 | 0.9900 | 70,237 |
| Oct 22, 2026 | 1.06 | 1.07 | 1.01 | 1.01 | 10,432 |
| Oct 21, 2026 | 1.00 | 1.08 | 0.9078 | 1.05 | 50,978 |
| Oct 20, 2026 | 0.8900 | 0.9490 | 0.8900 | 0.9000 | 12,611 |
| Oct 19, 2026 | 0.9028 | 0.9588 | 0.8500 | 0.8501 | 8,046 |
| Oct 16, 2026 | 0.9900 | 0.9900 | 0.9299 | 0.9299 | 9,198 |
| Oct 15, 2026 | 0.9300 | 0.9613 | 0.9300 | 0.9400 | 1,957 |
| Oct 14, 2026 | 0.9500 | 0.9500 | 0.9250 | 0.9300 | 4,822 |
| Oct 13, 2026 | 0.9594 | 0.9600 | 0.9102 | 0.9400 | 14,916 |
| Oct 12, 2026 | 0.9100 | 0.9800 | 0.8677 | 0.9699 | 7,697 |
| Oct 9, 2026 | 0.9665 | 0.9665 | 0.8500 | 0.9532 | 1,453 |
| Oct 8, 2026 | 1.01 | 1.01 | 0.9900 | 1.00 | 6,053 |
| Oct 7, 2026 | 0.9800 | 1.04 | 0.8500 | 1.04 | 61,505 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Manieu Alexandre Weinstein | Director | Purchase | 833.3K | $1.25M | Oct 23, 2026 |
| Manieu Alexandre Weinstein | Director | Purchase | 833.3K | -- | Oct 23, 2026 |
| Manieu Alexandre Weinstein | Director | Option Exercise | 641 | -- | Aug 25, 2026 |
 SHORRER DORON | Director | Grant/Award | 31.6K | -- | Aug 20, 2026 |
| Manieu Alexandre Weinstein | Director | Grant/Award | 180.0K | -- | Aug 20, 2026 |
| Manieu Alexandre Weinstein | Director | Expiration (Short) | 625.0K | -- | Jun 30, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Alexandre Weinstein · joint filing· may incl. warrants· filed Oct 2026 | 4.6M | 33.9% | 13D |
MERCHANT ADVENTURE FUND, L.P. · may incl. warrants· filed Apr 2025 | 1.3M | 9.5% | 13G |
Shayna LP · may incl. warrants· filed Oct 2025 | 407.0K | 3.0% | 13G |
Gunn John A. · may incl. warrants· stale · filed Feb 2024 | 307.3K | 2.3% | 13G |
Regals Capital Management LP · may incl. warrants· stale · filed Feb 2024 | 255.2K | 1.9% | 13G |
 Aberman Zami Director | 144.2K | 1.1% | FORM 4 |
 Zalts Liat Chief Financial Officer | 92.8K | 0.7% | FORM 4 |
Yaky Yanay · may incl. warrants· filed May 2025 | 60.6K | 0.5% | 13D |
 SHORRER DORON Director | 38.2K | 0.3% | FORM 4 |
 Birger Pinhas Doron Director | 19.2K | 0.1% | FORM 4 |
Insiders
- Manieu Alexandre WeinsteinDirector
- SHORRER DORONDirector
- Ajchenbaum EitanDirector
- YANAY YAKYChief Executive Officer
- Levi Rami AvrahamDirector
- Shemesh-Rasmussen MaitalDirector
- Aberman ZamiDirector
- Zalts LiatChief Financial Officer
- Birger Pinhas DoronDirector
- Franco-Yehuda ChenChief Financial Officer
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies.
Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders.
The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease.
Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome.
The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
based on 13.44M shares outstanding
IL30d Avg
59.95K
60d Avg
40.47K
90d Avg
35.32K